

**PHILOGEN S.p.A.****2026 CALENDAR OF CORPORATE EVENTS**

**Siena (Italy), 29 January 2026** – Philogen S.p.A. (the "Company" or "Philogen") discloses, pursuant to art. 2.6.2 paragraph 1 of the Market Regulation organised and managed by Borsa Italiana S.p.A., the calendar of corporate events relating to the financial year 2026.

- **March 27, 2026**

Board of Directors' Meeting for the approval of the Draft Financial Statements and the 2025 Consolidated Financial Statements

- **April 29, 2026**

Shareholders' Meeting for the approval of the 2025 Financial Statements

- **May 12, 2026**

Board of Directors' meeting for the approval of the press release containing a quarterly report with selected information indicative of the performance of the business relating to the first quarter of 2026 (*net financial position and progress of the main clinical trials with Nidlegy™ and Fibromun*)

- **September 23, 2026**

Board of Directors' Meeting for the approval of the Half-Yearly Financial Report as at 30 June 2026

- **November 12, 2026**

Board of Directors' meeting for the approval of the press release containing a quarterly report with selected information indicative of the performance of the business relating to the third quarter of 2026 (*net financial position and progress of the main clinical trials with Nidlegy™ and Fibromun*)

Philogen will promptly communicate any changes with respect to the dates communicated. The calendar of corporate events is also available on the Company's website [www.philogen.com](http://www.philogen.com) in the "investors/financial-calendar" section

\* \* \*

**Description of the Philogen Group**

Philogen is an Italian-Swiss company active in the biotechnology sector, specialized in the research and development of pharmaceutical products for the treatment of diseases with a high lethality rate. The Group mainly discovers and develops targeted anticancer drugs, exploiting high-affinity ligands for tumor markers (also called tumor antigens). These ligands – human monoclonal antibodies or small organic molecules – are identified through *Antibody Phage Display Libraries* and *DNA-Encoded Chemical Libraries* technologies.

The Group's main therapeutic strategy for the treatment of these diseases is represented by what is known as *tumor targeting*. This approach is based on the use of ligands capable of selectively conveying very powerful therapeutic active ingredients (such as, for example, pro-inflammatory cytokines) to the tumor mass, sparing healthy tissues. Over the years, Philogen has mainly developed ligands based on monoclonal antibodies, specific for antigens expressed in blood vessels associated with tumors, but not expressed in blood vessels associated with healthy tissues. These antigens are usually more abundant and more stable than those expressed directly on the surface of cancer cells. This approach, known as *vascular targeting*, is used for most of the projects pursued by the Group.

The Group's goal is to generate, develop and commercialize innovative products for the treatment of diseases for which medical science has not yet identified satisfactory therapies. This is achieved by leveraging (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeting tissues affected by the disease, (iii) experience in the production and development of drugs and (iv) the broad portfolio of patents and intellectual property rights.

Although the Group's drugs are mainly oncological applications, the *targeting* approach is potentially applicable to other diseases as well, such as certain chronic inflammatory diseases.

\* \* \*

**FOR FURTHER INFORMATION:**

**Philogen - Investor Relations**

[IR@philogen.com](mailto:IR@philogen.com) - Emanuele Puca | *Investor Relator*